To Study the Effects of Host Genetic Factors on Liver Cirrhosis and Hepatocellular Carcinoma (HCC)
Recruitment status was Recruiting
The purpose of this study is to identify genetic determinants of susceptibility to liver cirrhosis and hepatocellular carcinoma. It will assist in predicting individual risks of disease progression and would help to clarify pathophysiologic mechanisms of liver cirrhosis and hepatocellular carcinoma.
|Study Design:||Observational Model: Case Control
Time Perspective: Retrospective
|Official Title:||Functional Genomics and Proteomics Towards and Understanding of Cell Signaling and Diseases--- Genomic and Proteomic Analyses of Liver Cells During Hepatitis Virus Infections and Cell Therapy (4/4)|
liver tissue (non-tumor part)
|Study Start Date:||April 2008|
|Estimated Study Completion Date:||December 2009|
|Estimated Primary Completion Date:||December 2009 (Final data collection date for primary outcome measure)|
HCC patients without liver cirrhosis
HCC patients with liver cirrhosis
Hepatocellular carcinoma (HCC) usually occurs in cirrhotic liver. Only 10-30% of HCC occur in non-cirrhotic liver. It has been suggested that etiological factors may differ for HCC which develop in cirrhotic liver: HCC in non-cirrhotic liver might be less often associated with viral infection and chronic alcoholism than HCC in cirrhotic livers. However, in any individual, the factors that determine HCC with or without cirrhosis remain unknown.
Cirrhosis is the end of fibrosis progression. The progress of liver fibrosis is a complex progress involving many cytokines related to activation of the hepatic stellate cells and progressive accumulation of extracellular matrix. The key enzymes responsible for deposition and degradation of all the protein component of extracellular matrix and basement membrane are matrix metalloproteinases.
To assess whether genetic variations in cytokines and matrix metalloproteinases result in diversity of liver cirrhosis and HCC, we conduct a case-control study of single nucleotide polymorphism analysis.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00709085
|Contact: Tzu-Min Hung, M.S.||886-2-2312-3456 ext email@example.com|
|National Taiwan University Hospital||Recruiting|
|Contact: Ming-Fu Chang, Ph.D. 886-2-2312-3456 ext 88217 firstname.lastname@example.org|
|Principal Investigator: Ming-Fu Chang, Ph.D.|
|Study Chair:||Ming-Fu Chang, Ph.D.||National Taiwan University College of Medicine|